Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Sakamoto, Kentaro ^a   Kawamura, Mitsunobu ^b   Kohro, Takahide ^c   Omura, Masao ^d   Watanabe, Takayuki ^e   Ashidate, Keiko ^f   Horiuchi, Toshiyuki ^g   Hara, Hidehiko ^a   Sekine, Nobuo ^h   Chin, Rina ⁱ   Tsujino, Motoyoshi ^j   Hiyoshi, Toru ^k   Tagami, Motoki ^l   Tanaka, Akira ^m   Mori, Yasumichi ⁿ   Inazawa, Takeshi ^o   Hirano, Tsutomu ^p   Yamazaki, Tsutomu ^q   Shiba, Teruo ^a,r   Isogawa, Akihiro ^s   Iijima, Raisuke ^s   Kitazawa, Toru ^s   more..

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b TOKYO TEISHIN HOSPITAL   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d YOKOHAMA ROSAI HOSPITAL   (Japan)

^e YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^f Kudanzaka Hospital   (Japan)

^g Toshima Tokyo Metropolitan Hospital   (Japan)

^h TOKYO KOSEI NENKIN HOSPITAL   (Japan)

ⁱ TOKYO KYOSAI HOSPITAL   (Japan)

^j TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^k JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^l Sanraku Hospital   (Japan)

^m KAGAWA NUTRITION UNIVERSITY   (Japan)

ⁿ TORANOMON HOSPITAL   (Japan)

^o Kashiwa Hospital   (Japan)

^p SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^r MITSUI MEMORIAL HOSPITAL   (Japan)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATININE; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PITAVASTATIN; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMMON COLD; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; ECZEMA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84946962341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138332     Document Type: Article

References (49)

1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ. 1998; 316:823-8. PMID: 9549452
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371:117-25. doi: 10.1016/S0140-6736(08)60104-X PMID: 18191683
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA, 2001; 285:2486-2497 PMID: 11368702
4. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34:3035-87. doi: 10.1093/eurheartj/eht108 PMID: 23996285
5. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013; 36:2271-9. doi: 10.2337/dc12-2258 PMID: 23418368\
6. Mabuchi H, Inazu A, Higashikata T, Nohara A, Koizumi J. The current status of medicinal therapy for hyperlipidemia-Kanazawa Lipid Assessment Survey (K-LAS) [in Japanese]. Prog Med. 2000; 20:1629-1639.
7. Hosokawa M, Hamasaki A, Nagashima K, Harashima S, Toyoda K, Fujita Y, et al. Lack of goal attainment regarding the low-density lipoprotein cholesterol level in the management of type 2 diabetes mellitus. Intern Med. 2013; 52:2409-15. PMID: 24190144
8. Katakami N, Kaneto H, Osonoi T, Saitou M, Takahara M, Sakamoto F, et al. Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients. Atherosclerosis. 2011 Feb; 214:442-7. doi: 10.1016/j.atherosclerosis.2010.10.035 PMID: 21146820
9. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005; 96:556-63. PMID: 16098311
10. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999; 99:2858-60. PMID: 10359727
11. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61:427-36. doi: 10.1016/j.jacc.2012.08.1026 PMID: 23265341
12. El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007; 49:547-53. PMID: 17276177
13. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol, 2008; 51:1512-24 doi: 10.1016/j.jacc.2008.02.034 PMID: 18402913
14. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003; 57:363-368. PMID: 12846338
15. Lally SE, Owens D, Tomkin GH. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and nondiabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia. 2007 Jan; 50(1):217-9. PMID: 17102949
16. Inazawa T, Sakamoto K, Kohro T, Iijima R, Kitazawa T, Hirano T, et al. RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids Health Dis. 2013; 12:142. doi: 10.1186/1476-511X-12-142 PMID: 24094079
17. Japan Atherosclerosis Society. Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. J Atheroscler Thromb. 2007 Apr:5-57. PMID: 17566346
18. Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients. Nucleosides Nucleotides Nucleic Acids. 2010; 29:321-4. doi: 10.1080/15257771003741323 PMID: 20544514
19. Ogawa H, Matsui K, Saito Y, Kaneko K. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study-. Circ J. 2014; 78:2512-5. PMID: 25186922
20. Hu M, Lui SS, Ko GT, Tomlinson B. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. Int J Cardiol. 2013; 168:3071-3. doi: 10.1016/j.ijcard.2013.04.091 PMID: 23642826
21. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, et al. Clinical significance of small dense lowdensity lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol. 2004; 24:558-63. PMID: 14726414
22. Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010; 56:967-76. doi: 10.1373/clinchem.2009.137489 PMID: 20431054
23. Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005; 7:88-97. PMID: 15642080
24. Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010; 9:20. doi: 10.1186/1475-2840-9-20 PMID: 20492655
25. Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010; 12:210-8. doi: 10.1111/j.1463-1326.2009.01152.x PMID: 20151997
26. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875-881. PMID: 8782636
27. Ginsberg HN. Insulin resistance and cardiovascular disease J Clin Invest. 2000; 106:453-8. PMID: 10953019
28. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993; 94:350-6. PMID: 8475928
29. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001; 154:229-236 PMID: 11137104
30. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus J Am Coll Cardiol. 2004; 43:2219-24. PMID: 15193683
31. Bozzetto L, Annuzzi G, Corte GD, Patti L, Cipriano P, Mangione A, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011; 217:142-148. doi: 10.1016/j.atherosclerosis.2011.03.012 PMID: 21481394
32. Masuoka H, Kamei S, Ozaki M, Kawasaki A, Shintani U, Ito M, et al. Predictive value of remnant-like particle cholesterol as an indicator of coronary artery stenosis in patients with normal serum triglyceride levels. Internal Medicine, 2000; 39:540-546. PMID: 10888209
33. Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res. 2007; 48:699-708. PMID: 17130282
34. Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki T, Kita Y, et al. The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis. 2007; 190:216-23. PMID: 16529754
35. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010; 41:203-9. doi: 10.1161/STROKEAHA.109.564708 PMID: 19940278
36. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met.Am J Med. 2006; 119:676-83. PMID: 16887414
37. Bozentowicz-Wikarek M, Kocelak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis-guidelines vs. reality. Pharmacol Rep. 2012; 64:377-85. PMID: 22661189
38. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009; 53:316-22. doi: 10.1016/j.jacc.2008.10.024 PMID: 19161879
39. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005; 112:3375-83. PMID: 16316964
40. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a PMID: 24222016
41. Downs J, Good C. New Cholesterol Guidelines: Has Godot Finally Arrived? Ann Intern Med. 2014; 160:354-5. doi: 10.7326/M13-2850 PMID: 24473934
42. Martin SS, Blumenthal RS. Concepts and Controversies: The 2013 American College of Cardiology/American Heart Association Risk Assessment and Cholesterol Treatment Guidelines. Ann Intern Med. 2014; 160:356-8. doi: 10.7326/M13-2805 PMID: 24473832
43. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. Can J Cardiol. 2014; 30:377-80. doi: 10.1016/j.cjca.2014.01.009 PMID: 24589194
44. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J Clin Lipidol. 2014; 8:29-60. doi: 10.1016/j.jacl.2013.12.005 PMID: 24528685
45. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359:1343-1356. doi: 10.1056/NEJMoa0804602 PMID: 18765433
46. Holme I, Boman K, Brudi P, Egstrup K, Gohlke-Baerwolf C, Kesäniemi YA, et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial. Am J Cardiol. 2010; 105:1802-1808. doi: 10.1016/j.amjcard.2010.01.363 PMID: 20538134
47. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181-2192. doi: 10.1016/S0140-6736(11)60739-3 PMID: 21663949
48. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-1278. PMID: 16214597
49. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360:1395-1407. doi: 10.1056/NEJMoa0810177 PMID: 19332456